Geneva, Switzerland and Boston, MA -December 7, 2017 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that company management will participate in the BMO Prescriptions for Success Healthcare Conference on December 14th, 2017, in New York City.
ObsEva's presentation will take place on Thursday, December 14th, 2017, at 3.00 p.m. Eastern Time (ET). A webcast will be available in the "Investors" section of ObsEva's website www.ObsEva.com.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.
###
Media Contact:
Liz Bryan
Spectrum Science
lbryan@spectrumscience.com
+1 202-955-6222 x2526
Company Contact:
CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact
Mario Corso
Senior Director, Investor Relations
mario.corso@obseva.com
+1 781-366-5726
